Tony Arulanandam

Company: Cytovia Therapeutics

Job title: SVP and Head R&D

Seminars:

Reinventing Autoimmune Disease & Cancer Treatment by Harnessing NK Cells 11:30 am

Validated Flex-NK™ bispecific antibody scaffold for developing next generation of NK cell redirected antibody therapeutics for Autoimmune disease and Cancer CD38 a well differentiated target for B cell mediated autoimmune diseases and the unique mechanism of action of CYT-338 NK cell engaged Cytovia 2.0 emerging pipeline based on NK cell therapy’s for the treatment of…Read more

day: Day Two